ERIC KRAMER: Open Payments
NPI 1750470886 · MARRERO, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$847 in 42 payments from 12 companies in 2025. Trend: 2023 $682 · 2024 $1,088 · 2025 $847
Food & beverage: $847
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 10 | $225 |
| Alkermes, Inc. | 11 | $191 |
| Otsuka America Pharmaceutical, Inc. | 6 | $128 |
| Vanda Pharmaceuticals Inc. | 3 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| ABBVIE INC. | 2 | $44 |
| Lundbeck LLC | 2 | $35 |
| Neurocrine BioSciences, Inc. | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
Products named: ARISTADA, SPRAVATO, REXULTI, INVEGA, FANAPT, UZEDY, VRAYLAR, ABILIFY ASIMTUFII.
Industry payments across LA — which companies pay providers there.
